Exagen (NASDAQ:XGN – Get Free Report) and Hims & Hers Health (NYSE:HIMS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.
Volatility and Risk
Exagen has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500.
Institutional and Insider Ownership
75.2% of Exagen shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Exagen and Hims & Hers Health”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exagen | $71.12 million | 2.93 | -$19.95 million | ($0.81) | -10.60 |
| Hims & Hers Health | $2.58 billion | 2.50 | $128.37 million | ($0.63) | -43.79 |
Hims & Hers Health has higher revenue and earnings than Exagen. Hims & Hers Health is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Exagen and Hims & Hers Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exagen | 1 | 0 | 7 | 1 | 2.89 |
| Hims & Hers Health | 1 | 11 | 3 | 0 | 2.13 |
Exagen currently has a consensus price target of $10.12, indicating a potential upside of 17.87%. Hims & Hers Health has a consensus price target of $32.43, indicating a potential upside of 17.55%. Given Exagen’s stronger consensus rating and higher possible upside, equities analysts plainly believe Exagen is more favorable than Hims & Hers Health.
Profitability
This table compares Exagen and Hims & Hers Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exagen | -26.61% | -104.46% | -28.93% |
| Hims & Hers Health | -5.51% | -6.51% | -1.20% |
Summary
Hims & Hers Health beats Exagen on 8 of the 15 factors compared between the two stocks.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
About Hims & Hers Health
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
